Detalhe da pesquisa
1.
The Evolving Role of Rituximab in Adult Minimal Change Glomerulopathy.
Am J Nephrol
; 45(4): 365-372, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28315862
2.
Thrombosis Rates and Genetic Thrombophilia Risk Among Patients With Advanced Germ Cell Tumors Treated With Chemotherapy.
Clin Genitourin Cancer
; : 102086, 2024 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38697880
3.
RNA-Based Homologous Recombination Deficiency Signature Detects Homologous Recombination Deficiency-RNA+ Patients With and Without Homologous Recombination Repair Gene Pathogenic Alterations in Men With Prostate Cancer.
JCO Precis Oncol
; 7: e2300378, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-38061006
4.
Prognostic value of galectin-1 and galectin-3 expression in localized urothelial bladder cancer.
Transl Androl Urol
; 12(2): 228-240, 2023 Feb 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-36915891
5.
A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer.
Prostate Cancer Prostatic Dis
; 25(4): 762-769, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35292724
6.
The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma.
Cancers (Basel)
; 14(15)2022 Aug 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35954493
7.
Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma.
J Immunother Cancer
; 10(10)2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36252996
8.
Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab.
J Immunother Cancer
; 9(9)2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34518292
9.
LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types.
J Immunother Cancer
; 9(3)2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33653800
10.
Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes.
Cancer Med
; 10(7): 2341-2349, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33650321
11.
Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma.
Biomark Res
; 9(1): 80, 2021 Nov 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34732251
12.
Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide.
Clin Cancer Res
; 27(14): 4077-4088, 2021 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33820782
13.
The Role of Targeted Therapy in the Management of High-Risk Resected Kidney Cancer: What Have We Learned and How Will It Inform Future Adjuvant Trials.
Cancer J
; 26(5): 376-381, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32947305
14.
The Immunotherapy Landscape in Renal Cell Carcinoma.
BioDrugs
; 34(6): 733-748, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-33048299
15.
Androgen receptor variant-driven prostate cancer II: advances in clinical investigation.
Prostate Cancer Prostatic Dis
; 23(3): 367-380, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32094489
16.
Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations.
Prostate Cancer Prostatic Dis
; 23(3): 381-397, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32139878
17.
PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial Carcinoma.
Clin Genitourin Cancer
; 18(6): 509-513, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32482566
18.
CDK12-Mutated Prostate Cancer: Clinical Outcomes With Standard Therapies and Immune Checkpoint Blockade.
JCO Precis Oncol
; 4: 382-392, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32671317
19.
Germline Testing in Prostate Cancer: Implementation and Disparities of Care.
JCO Oncol Pract
; 19(5): 221-223, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36720077
20.
Can RECIST response predict success in phase 3 trials in men with metastatic castration-resistant prostate cancer?
Prostate Cancer Prostatic Dis
; 21(3): 419-430, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29858595